valu usd unless otherwis note
strong result lower ep account
acceler opex spend
view momentum continu lower
ep estim account manag expect increas
oper expens spend believ right long-term move
compani increas spend go toward growth-ori
initi enabl expand remain
premium player surgic robot market
post strong full result recal earlier januari
pre-announce better expect non-gaap revenu
y/i fce market close yesterday
announc full result compani report
non-gaap ep fce note made
contribut launch intuit foundat reduc
non-gaap ep non-gaap oper margin came
exclud contribut fce
non-gaap fce
expect oper expens growth acceler
recal previous announc world-wide procedur
guidanc rbce separ yesterday provid
full guidanc manag expect gross margin
fce higher expect y/
acceler spend follow area informat
capabl expans ou market autom manufactur
key product sp ion vision advanc instrument
lower ep estim rais revenu
estim y/i owe mainli higher
system revenu howev lower non-gaap ep estim
y/i account increas
spend also rais revenu estim
y/i non-gaap ep estim declin
y/i
momentum continu build compani invest
heavili ahead upcom competit soft tissu robot
competit come believ clear runway
least next month addit heavili
reinvest recent upsid advanc new system/instru
technolog market develop work expand robot
penetr intern market new technolog front
broaden roll-out sureform surgic stapler
expand indic new da vinci sp system transor
indic file manag also wait fda
clearanc ion flexibl cathet system expect perform
first clinic case use augment realiti softwar
price prior trade day market close estimate unless otherwis note
believ share perform line
peer group follow key reason
 da vinci prostatectomi hysterectomi procedur
combin grow mid-singl digit y/i
penetr target us prostatectomi
us hysterectomi market robot respect
two procedur compris total
 procedur grow well
market categori model
market-lik slightli above-market growth dvp
gener surgeri market repres main near-
term procedur growth driver recent strong
hernia/colorect trend appear sustain
urolog gynecolog market combin
hernia colorect bariatr thorac
recent channel check robot survey give
us confid real sustain
gener surgeri
pictur continu execut growth
strategi gener surgeri intern
pipelin expand remain confid two
import procedur growth driver
colorect hernia sustain
long runway ahead intern market system
front receiv fda approv da vinci sp
urolog procedur follow approv
transor colorect addit
earli human clinic experi prototyp flexibl
catheter-bas robot platform initi use
lung biopsi file flexibl
cathet platform await fda approv add
yet anoth growth opportun addit
analytics/imag opportun next-gener
system develop
upcom catalyst event
commerci da vinci sp commerci
ion lung biopsi system annual sage confer
commerci risk fda regulatori risk
competit risk legal risk reimburs risk
bloomberg capit market estim upside/downside/target
base scenario assum price target
base weight intrins valu calcul
dcf analysi weight
intrins valu calcul ev/ebitda analysi
assum continu increas
penetr us gener surgeri intern surgic
market estim world-wide instal
base system da vinci procedur
perform annual includ lung biopsi
upsid scenario assum share rise
base dcf model termin valu ev/ebitda
multipl assum continu increas
penetr us gener surgeri intern surgic
market addit assum acceler
upgrad opportun da vinci success
penetr natur orific procedur sp
multibillion-dollar lung biopsi opportun ion
estim world-wide instal base
system da vinci procedur perform
annual includ lung biopsi
downsid scenario assum share fall
base dcf model termin valu ev/ebitda
multipl also assum ultim penetr
gener surgeri market disappoint da vinci sp
competit robot entri us forc
addit pressur da vinci price estim
world-wide instal base nearli system
da vinci procedur perform annual
includ lung biopsi assum ramp
lung biopsi platform slow intervent pulmonologist
want see clinic data adopt
perform dcf ev/ebitda analysi arriv intrins valu
share dcf analysi use wacc assum termin valu ev/ebitda
multipl base dcf analysi estim intrins valu
approxim separ conduct ev/ebitda analysi use publicli
trade med-tech compar compani analysi point averag forward ev/
ebitda multipl large-cap med-tech compani super premium large-cap
med-tech diagnost compani assign target non-gaap ebitda
multipl premium peer group owe expect
superior top-lin growth rel peer given isrg above-averag oper
margin multipl equat intrins valu deriv price target
assign weight intrins valu calcul dcf analysi
weight intrins valu calcul ev/ebitda analysi
price target impli return support sector perform rate
risk rate price target
face risk typic medic devic compani risk price target
rate includ slower-than-expect gener surgeri procedur growth
one lead indic futur system placement slower-than-expect system ramp
da vinci xi sp ion procedur declin two three core
market hysterectomi prostatectomi competit risk titan
medic expect gain fda/eu approv robot system
time frame potenti neg public futur clinic studi surgic societi
advers event on-going lawsuit fda regulatori risk surround new robot
platform devic reimburs risk risk
found current market leader world-wide robot market
compani went public receiv fda approv two key indic benign
prostatectomi hysterectomi focus five key surgic specialti
urolog surgeri gynecolog surgeri gener surgeri cardiothorac surgeri head
neck surgeri urolog gynecolog procedur repres around half total
world-wide procedur perform da vinci system incorpor delawar
corpor headquart locat sunnyval california compani manufactur
da vinci system facil sunnyval california instrument made
sunnyval facil mexicali mexico facil
amort intang
